What is Exicure's market cap?

Exicure (XCUR) has a market capitalization of $11.2M and trades on NASDAQ.

Who are Exicure's competitors?

Exicure's key competitors include Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Oric Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Exicure partner with?

Exicure's notable partners include GPCR Therapeutics Inc, Bluejay Therapeutics, Inc., Flashpoint Therapeutics, Inc., and others.

What subsidiaries does Exicure have?

Exicure's subsidiaries include GPCR Therapeutics USA Inc., KC Creation Co., Ltd..

Where is Exicure headquartered?

Exicure is headquartered in United States of America and employs approximately 5 people. It has been publicly traded since 2018.

Exicure

XCUR

Exicure, Inc. is a biotechnology company that has transitioned from developing proprietary nucleic acid therapies to exploring strategic growth through acquisitions and partnerships.

Market cap

$11.15M-73.2%

Table of contents

Earnings

Q1 2026 report

May 29, 2026

EPS-$0.29Beat by $18.31

Read the full report

Next report

Date not yet announced

Competitors

By market cap

ALN

Alnylam Pharmaceuticals$37.2B-12.2%

Exelixis$14.0B+15.9%

Ionis Pharmaceuticals$9.2B+41.1%

Oric Pharmaceuticals, Inc.$1.2B+30.6%

Compass Therapeutics, Inc.$374.6M-15.3%

HIN

Vyome Holdings, Inc.$14.0M—

GT Biopharma$12.0M+75.3%

Exicure$11.2M-75.5%

By revenue growth

ALN

Alnylam Pharmaceuticals+82.6%

Exelixis+3.3%

Ionis Pharmaceuticals-7.4%

By net margin

Exelixis35.08%+7.1pp

ALN

Alnylam Pharmaceuticals11.72%+21.5pp

Ionis Pharmaceuticals-64.7%-36.3pp

Profile

Exicure, Inc. is a biotechnology company that has transitioned from developing proprietary nucleic acid therapies to exploring strategic growth through acquisitions and partnerships. The company currently focuses on advancing clinical-stage oncology treatments through its acquired subsidiary and leveraging its status as a publicly traded entity to attract new business combinations. Its core value proposition lies in its clinical assets for blood cancer and its pursuit of value-generating transactions, particularly within the Asian and domestic markets.

Competitive position

Exicure is currently in a transitional state, moving from a research-focused organization to a strategic vehicle for business combinations while maintaining early-to-mid-stage clinical oncology assets.

GeographiesUnited States, South Korea

Customer segmentsClinical Trial Participants, Pharmaceutical Companies

Business modelLicensing and Royalties, Research and Development, Strategic Acquisition

SuppliersContract Research Organizations (CROs), Clinical trial sites, Third-party manufacturers, Intellectual property licensors

CustomersPharmaceutical companies, Biotechnology firms, Oncology patients

CountryUnited States of America

Listed2018

Employees5.0

CEOJungsoo Kim

SectorHealthcare

IndustryBiotechnology

Websiteexicuretx.com

FilingsSEC EDGAR

Questions, answered.

What is Exicure's market cap?: Exicure (XCUR) has a market capitalization of $11.2M and trades on NASDAQ.
Who are Exicure's competitors?: Exicure's key competitors include Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Oric Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Exicure partner with?: Exicure's notable partners include GPCR Therapeutics Inc, Bluejay Therapeutics, Inc., Flashpoint Therapeutics, Inc., and others.
What subsidiaries does Exicure have?: Exicure's subsidiaries include GPCR Therapeutics USA Inc., KC Creation Co., Ltd..
Where is Exicure headquartered?: Exicure is headquartered in United States of America and employs approximately 5 people. It has been publicly traded since 2018.